FRAIZERON, SECUKINUMAB 150MG

Indications

• Moderate to severe plaque psoriasis
• Ankylosing spondylitis
• Psoriatic arthritis

Dosage

Children: Secukinumab is not typically indicated for use in paediatric populations. Refer to the BNF for Children for any specific guidance regarding potential use in children.

Adults: For adults, the initial dose of Secukinumab is typically 300 mg administered as two subcutaneous injections of 150 mg each at weeks 0, 1, 2, and 3, followed by a maintenance dose of 300 mg every 4 weeks. For specific conditions and adjustments, refer to the BNF.

Mechanism of action

Secukinumab binds to interleukin-17A, preventing it from interacting with its receptor and thus inhibiting the downstream signaling pathways that lead to inflammation. This mechanism is crucial in conditions characterized by excessive IL-17A production, contributing to the inflammatory process.

Pharmacodynamics

Secukinumab's pharmacodynamics involves the modulation of immune responses, particularly in the context of autoimmune diseases. By blocking IL-17A, it decreases the activation of T cells and other immune cells, leading to reduced levels of pro-inflammatory cytokines and chemokines. This results in decreased inflammation, tissue damage, and improvement in clinical symptoms.

Pharmacokinetics

Secukinumab has a half-life of approximately 27 days, allowing for less frequent dosing after an initial loading phase. It is administered subcutaneously, and its bioavailability is approximately 80%. The drug is primarily eliminated through the reticuloendothelial system. There is no significant renal or hepatic metabolism, which is important for patients with impaired renal or liver function.

Contra-indications

• Active infection
• History of serious or opportunistic infections
• Severe hypersensitivity to secukinumab or any component of the formulation
• Platelet count less than 150 x 10^9/microlitre
• Serum transaminases (ALT or AST) greater than 1.5 times the upper limit of normal
• History of diverticulitis or intestinal ulceration

Adverse effects

• Increased risk of infection
• Dyslipidaemia
• Neutropenia
• Thrombocytopenia
• Hypersensitivity reactions
• Skin reactions

Interactions

• Increased risk of immunosuppression when used with filgotinib

Precautions

• Caution in patients with chronic or recurrent infections
• Caution in elderly patients
• Monitor for signs and symptoms of infection
• Evaluate for tuberculosis before treatment initiation
• Consider anti-tuberculosis therapy in patients with a history of latent or active tuberculosis
• Patients should be up-to-date with immunisation schedule before initiating treatment

Pregnancy

Manufacturer advises to avoid unless essential due to limited information available.

Breast-feeding

Manufacturer advises to avoid due to no available information.

Storage

Store in a refrigerator (2–8°C) and protect from light.

Formulations

• Secukinumab 150 mg/1.14 ml solution for injection in pre-filled syringes
• Secukinumab 150 mg/1.14 ml solution for injection in pre-filled pens
• Secukinumab 300 mg/1.14 ml solution for injection in pre-filled syringes
• Secukinumab 300 mg/1.14 ml solution for injection in pre-filled pens